Prof. Humphries New Editor-in-Chief of Atherosclerosis

Title to develop into a leading platform in the field of atherosclerosis

Amsterdam, 3 June 2008 - Elsevier announced the new Editor-in-Chief of Atherosclerosis, Prof. Steve Humphries. Atherosclerosis is the official journal of the European Atherosclerosis Society and is affiliated with the Society of Atherosclerosis Imaging and Prevention and the International Atherosclerosis Society.

Professor Humphries is a leading researcher in the field of the Genetics of Cardiovascular Disease, with an international reputation. His research career spans more than 30 years and he has published more than 500 peer review papers, with a particular interest in Familial Hypercholesterolaemia which is a common genetic cause of premature heart disease. He is past President of the British Atherosclerosis Society, and has been a member of the Executive committee and for the last 4 years the Treasurer of the European Atherosclerosis Society.

Prof. Humphries comments: “We now have in place an excellent group of Associate Editors and are rapidly improving our reviewing and handling times. By the end of the year we aim that an accepted manuscript will be published in an issue within 5-6 months. Many of the papers published in Atherosclerosis in the last year, and especially some of the Review articles, are already showing a high down-load index and are being widely quoted”.

Graham Brumfield, Elsevier Publishing Editor for Cardiology journals adds “Atherosclerosis currently has an Impact Factor of 3.811 averaging over 50,000 full text downloads each month. Over the past 18 months publication times and author satisfaction have been improved and we are looking forward to working with Prof Humphries and with the EAS, IAS and the SAIP in further developing the title into a leading platform for the best clinical and research papers in the field of atherosclerosis”.

# # #

About Atherosclerosis
Atherosclerosis brings together clinical and research papers dealing with case studies of specific or general interest, new or unusual lipid syndromes, and the genetic basis and familial incidence of atherosclerosis and related diseases. High quality reports of controlled clinical trials of drugs or diets will be considered provided the paper deals with the mechanism of action of the drug or diet. Papers concerned with research and investigation on atherosclerosis, its complications, and related diseases, including: lipoprotein metabolism, arterial and vascular biology and disease, thrombosis, inflammation, disorders of lipid transport, diabetes and hypertension as related to atherosclerosis, and cardiovascular risk factors are welcomed as well.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Ingrid van Lier
Elsevier
+31 20 485 3919
i.lier@elsevier.com